BCTXZ — what changed in the latest 10-K
A section-by-section comparison of BCTXZ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-K · 2026-10-28 vs the prior 10-K · 2025-10-16
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| Business | Text added/removed | +126 | −73 | ~24 | 119 |
| Risk factors | Text added/removed | +178 | −216 | 0 | 0 |
| Legal proceedings | Text added/removed | 0 | −195 | ~12 | 9 |
| MD&A | Text added/removed | +35 | −214 | 0 | 0 |
| Market risk (Item 7A) | Text added/removed | 0 | −195 | ~9 | 9 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
Business
Text added vs the prior filing · source: 10-K · 2026-10-28
BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and …
BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.3 months for the Phase 3 sequence in BriaCell’s metastatic breast cancer patients vs. median overall survival reported in the literature and in its Phase 2 stu…
BriaCell Phase 1/2 Study of Bria-OTS™, the Company’s personalized off-the-shelf immunotherapy, in metastatic breast cancer is ongoing (listed on ClinicalTrials.gov as NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete resolution of a lung metast…
BriaCell is currently developing Bria-OTS™ and its advanced form, Bria-OTS+™, as a platform technology for personalized off-the-shelf immunotherapies for numerous types of cancer. The Company announced it has received from the FDA permission to proceed with Phase 1/2a clinical studies of Bria-BRES+™…
It is estimated by American Cancer Society Cancer Facts and Figures 2026, that approximately 324,580 people (321,910 women and 2,670 men) will be diagnosed with breast cancer in the United States in 2026. That means that every two minutes an American woman is diagnosed with breast cancer and more th…
Text removed vs the prior filing · source: 10-K · 2025-10-16
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 48
Item 7A Quantitative and Qualitative Disclosures About Market Risk 53
Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 53
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 54
Risk factors
Text added vs the prior filing · source: 10-K · 2026-10-28
An investment in our securities involves a high degree of risk. An investor should carefully consider the risks described below as well as other information contained in this Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission (“SEC”). The risks an…
Pre-clinical studies and initial clinical trials are not predictive of future results
Pre-clinical tests and Phase 1/2 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules.
Regulatory authorities may disagree with our analysis of data or may require the conduct of additional studies or analyses before permitting further development or marketing approval. Favorable results in early trials may not be repeated in later trials. Differences in trial design, patient populati…
A number of companies in the life sciences industry have suffered significant setbacks in advanced clinical trials, even after positive results in earlier trials. Clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals. Negative or…
Text removed vs the prior filing · source: 10-K · 2025-10-16
Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 48
Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations 48
Item 7A Quantitative and Qualitative Disclosures About Market Risk 53
Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 53
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 54
Legal proceedings
Text removed vs the prior filing · source: 10-K · 2025-10-16
BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and …
BriaCell Phase 1/2 Study of Bria-OTS™, BriaCell’s personalized off-the-shelf immunotherapy, also known as Bria-BRES™, in metastatic breast cancer is ongoing (listed on ClinicalTrials.gov as NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete reso…
It is estimated by the National Cancer Institute Cancer Facts and Figures that in 2025, approximately 319,750 people (316,950 women and 2,800 men) will be diagnosed with breast cancer in the United States. That means that every two minutes an American woman is diagnosed with breast cancer and more t…
According to the May 2025 “Global Oncology Trends 2025” report by the IQVIA Institute, the global market for cancer drugs (including immunotherapy drugs) is expected to reach nearly $441 billion by the end of 2029.
1 “Pivotal” is an industry term referring to a Phase 3 clinical study intended to show and confirm the safety and efficacy of a treatment.
MD&A
Text added vs the prior filing · source: 10-K · 2026-10-28
The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements based upon current expectations that inv…
The preparation of our consolidated financial statements in conformity with these accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities at the financial statement date and reported amounts …
BriaCell is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and destroy cancer cells. The Company is currently ad…
BriaCell has reported benchmark-beating patient survival and clinical benefit in metastatic breast cancer with median overall survival of 13.3 months in BriaCell’s metastatic breast cancer patients vs. 5.9-9.8 months for similar patients reported in the literature in its Phase 2 study of Bria-IMT™ c…
BriaCell Phase 1/2 Study of Bria-OTS™, BriaCell’s personalized off-the-shelf immunotherapy, in metastatic breast cancer is ongoing (listed on ClinicalTrials.gov as NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete resolution of a lung metastasi…
Text removed vs the prior filing · source: 10-K · 2025-10-16
Item 7A Quantitative and Qualitative Disclosures About Market Risk 53
Item 9 Changes In and Disagreements with Accountants on Accounting and Financial Disclosure 53
Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 54
Item 10 Directors, Executive Officers, and Corporate Governance 55
Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 66
Market risk (Item 7A)
Text removed vs the prior filing · source: 10-K · 2025-10-16
BriaCell Therapeutics Corp. (“Briacell” or the “Company”) is a clinical-stage biotechnology company that is developing novel immunotherapies to transform cancer care. Immunotherapies have come to the forefront in the fight against cancer as they harness the body’s own immune system to recognize and …
BriaCell Phase 1/2 Study of Bria-OTS™, BriaCell’s personalized off-the-shelf immunotherapy, also known as Bria-BRES™, in metastatic breast cancer is ongoing (listed on ClinicalTrials.gov as NCT06471673). The first patient treated with 4 inoculations of cells (single agent) demonstrated complete reso…
It is estimated by the National Cancer Institute Cancer Facts and Figures that in 2025, approximately 319,750 people (316,950 women and 2,800 men) will be diagnosed with breast cancer in the United States. That means that every two minutes an American woman is diagnosed with breast cancer and more t…
According to the May 2025 “Global Oncology Trends 2025” report by the IQVIA Institute, the global market for cancer drugs (including immunotherapy drugs) is expected to reach nearly $441 billion by the end of 2029.
1 “Pivotal” is an industry term referring to a Phase 3 clinical study intended to show and confirm the safety and efficacy of a treatment.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice